3 New Strong Buy Ratings from Top-Rated Analysts: 03/24/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• SanDisk (NASDAQ: SNDK) enjoys solid demand 
• Lockheed Martin Corp (NYSE: LMT) is soaring amid global tensions 
• Jazz Pharmaceuticals (NASDAQ: JAZZ) has over 50% potential upside in the coming year

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. SanDisk (NASDAQ: SNDK)

SanDisk is a NAND flash storage powerhouse behind SSDs, embedded tech, and removable storage. After a jaw-dropping 1,200% run fueled by AI hype, it’s now at the center of a high-stakes question: real demand—or a bubble about to burst?

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $709.71 — get current quote

Max 1-year forecast: $875.00

Why we're watching:

• Analyst support: SNDK enjoys 9 Strong Buy ratings, 3 Buy ratings, and 4 Hold ratings. See the ratings
• Citigroup researcher Asiya Merchant (a top 1% rated analyst) recently maintained her Strong Buy rating with an $875.00 price target; Cantor Fitzgerald researcher C.J. Muse (a top 3% rated analyst) recently maintained his Strong Buy rating with an $800.00 price target, demonstrating continued confidence in the company's positioning.
• Revenue is forecast to explode +74.35% to $15.6B in the coming year, with two-year growth projections of +198.22%, driven by surging AI infrastructure demand for high-performance storage solutions.
• Industry ranking context: SNDK is currently the #1 highest-rated stock in the Computer Hardware industry — but note that this market niche has an Industry Rating of D.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr, and SNDK's momentum continues to attract top-tier analyst support despite concerns about valuation.
• Component Grades: The company demonstrates exceptional growth credentials with an A rating in Growth and Sentiment, complemented by B ratings in Momentum and Financials, though Value and Safety receive C ratings reflecting elevated valuation concerns. See all 7 Zen Component Grades here

2. Lockheed Martin Corp (NYSE: LMT)

Lockheed Martin is a global defense giant powering advanced aircraft and missile systems. With delayed F-16 deliveries to Taiwan now back on track and new defense initiatives underway, it remains a cornerstone player—despite recent market swings.

Zen Rating: B (Buy) — see full analysis

Recent Price: $627.43 — get current quote

Max 1-year forecast: $740.00

Why we're watching:

• Analyst support: We’ll be real with you: the coverage is mixed, with 12 total analysts providing 2 Strong Buy ratings, 1 Buy rating, 8 Hold ratings, and 1 Strong Sell rating. See the ratings
• Looking at the bullish parties, Susquehanna researcher Charles Minervino (a top 3% rated analyst) recently maintained his Strong Buy rating with a $740.00 price target (+17.94% upside), the highest among covering analysts.
• Truist Securities' Michael Ciarmoli (a top 1% rated analyst) recently upgraded the stock to Strong Buy with a $605.00 price target, signaling improving conviction despite near-term headwinds. 
• The company demonstrates exceptional financial strength with a 125.85% return on equity and earnings forecast to grow +40.01% to $30.19 per share, driven by strong defense spending and growing international demand.
• Industry ranking context: LMT is currently the 10th highest-rated stock out of 76 in the Defense industry, which has an Industry Rating of C.
• Zen Rating highlights: LMT is B (Buy) rated according to our Zen Ratings. Its defensive qualities and strong Component Grades (see next bullet) make it attractive for risk-conscious investors seeking exposure to defense spending trends.
• Component Grades: Lockheed Martin shows exceptional safety with an A rating in Safety, complemented by strong B ratings in Value, Momentum, and Financials, though Growth and Sentiment receive C ratings reflecting mature market dynamics. See all 7 Zen Component Grades here

3. Jazz Pharmaceuticals (NASDAQ: JAZZ)

Jazz Pharmaceuticals is a global biopharma player targeting high-need diseases. With promising oncology data heading into AACR 2026 and strong analyst backing, the stock sits near its lows—setting up a potential upside surprise.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $180.62 — get current quote

Max 1-year forecast: $275.00

Why we're watching:

• Analyst support: JAZZ enjoys 7 Strong Buy ratings, 3 Buy ratings, and 1 Hold rating, resulting in a Strong Buy consensus. See the ratings here
• Bank of America researcher Jason Gerberry (a top 15% rated analyst) recently maintained his Strong Buy rating with a $275.00 price target (+52.25% upside), the highest on the Street.
• Wells Fargo researcher Mohit Bansal (a top 15% rated analyst) recently maintained his Strong Buy rating with a $250.00 price target following recent conference presentations.
• The company demonstrates strong profitability with a 17% profit margin and robust return on equity of 44.06%, while revenue is expected to grow +6.17% to $4.5B with improving earnings trajectory.
• Industry ranking context: JAZZ is currently the 4th highest-rated stock in the Biotech industry, which has an Industry Rating of F, making it a standout performer in a challenging sector.
• Zen Rating highlights: As an A-rated stock, JAZZ ranks in the top 5% of the 4600+ stocks we track, with outstanding fundamentals: It boasts Component Grades of A for Value and Growth, complemented by B ratings in Financials and AI. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.